⚠️ Serious warning: Nothing on this website is approved by any physician. Doz is only a tool to help physicians and to search drugs easily. Taking medicines without medical supervision can be fatal.

Alogliptin

آلوگلیپتین

⚠ Unverified

🍽️ Alimentary Tract And MetabolismDPP-4 inhibitor

🤰 Pregnancy:Use with caution 🤱 Breastfeeding:Use with caution 👶 Children:Use with caution 👴 Older adults:No specific problem stated 🇮🇷 Not found in Iran list ⛔ 1 contraindications 🇺🇸 FDA approved (NDA) NDA022271 ATC A10BH04

Market / country: 🇺🇸 USA

Nesina (US)

🧮 Dose calculator

Disease / regimen

Type 2 diabetes mellitus · Regimen source: FDA Nesina · 2.1

• Do not split tablets. FDA Nesina · 2.1

Formulation

Age *

Weight (kg) (optional)

Enter age (weight is optional for this regimen).

🛡️ Safety & information

Contraindications

⛔ History of serious hypersensitivity to alogliptin. FDA Nesina · 4

Warnings

• Pancreatitis; heart failure; hypoglycaemia with insulin or sulfonylureas; hypersensitivity; severe arthralgia; bullous pemphigoid. FDA Nesina · 5
• Hepatic effects (check liver tests before starting). FDA Nesina · 5.4

Renal adjustment

• eGFR < 60: CrCl 30–<60: 12.5 mg; <30 and ESRD: 6.25 mg once daily. FDA Nesina · 2.2

Formulations

25 mg tablet — tablet 🇺🇸 USA FDA Nesina · 3
12.5 mg tablet — tablet 🇺🇸 USA FDA Nesina · 3
6.25 mg tablet — tablet 🇺🇸 USA FDA Nesina · 3

👥 Special populations

🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Nesina · 8.1
“Risk Summary Limited data with NESINA in pregnant women are not sufficient to determine a drug-associated risk for major birth defects or miscarriage.”
🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Nesina · 8.2
“Risk Summary There is no information regarding the presence of alogliptin in human milk, the effects on the breastfed infant, or the effects on milk production.”
👶 ChildrenUse with caution
The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Nesina · 8.4
“The safety and effectiveness of NESINA have not been established in pediatric patients.”
👴 Older adultsNo specific problem stated
Label: no specific difference or dose adjustment stated for older adults. FDA Nesina · 8.5
“No overall differences in safety or effectiveness were observed between patients 65 years and over and younger patients.”
⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.

🔗 Reference links

FDA (approval record)NDA022271
DailyMed (FDA label)FDA Nesina
MedlinePlus (NIH)Alogliptin
WHO ATC/DDDA10BH04
Darooyab (Iran)❌ None

🇮🇷 Not found in Iran list Darooyab · search

Darooyab lists no registered dosage form or brand for this drug. This does not prove it is unavailable.

📚 Reference status for this drug

Shows which sources have references recorded for this drug and which do not.

FDA label (DailyMed)✅ Present
FDA Nesina · 3 FDA Nesina · 2.1 FDA Nesina · 4 FDA Nesina · 5 FDA Nesina · 5.4 FDA Nesina · 2.2 FDA Nesina · SPL approval / marketing category FDA Nesina · 8.1 FDA Nesina · 8.2 FDA Nesina · 8.4 FDA Nesina · 8.5
UK SmPC (eMC / MHRA)❌ Not present
Published guideline❌ Not present
Licensed reference (medical school)❌ Not present
Iranian leaflet (IFDA)❌ Not present
Pharmacy website (secondary, unreliable)✅ Present
Darooyab · search
Clinical review⚠ Unverified